PRODUCTS & SERVICES
Two of our management team - our CEO, Pavol Cekan, and Chief Scientific Officer, Evan Paul, traveled to New York this week to meet our Advisory board members and discuss the next steps after finalizing the retrospective clinical validation of our Multiplex8+ breast cancer diagnostic test.
We are proud to have on board - Prof. Tom Tuschl from Rockefeller University, a pioneer in RNA biology, and Dr. Jorge Reis-Filho, Chief of Experimental Pathology at the Memorial Sloan Kettering Cancer Center, one of the top world-class experts in the field of cancer.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.